Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Relatlimab in Metastatic Urothelial Cancer with ARID1A/KDM6A Mutations
NCT04953104Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2021
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, relatlimab in urothelial carcinoma (UC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2021; status: active, not recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04953104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953104.